Skip to main content
Premium Trial:

Request an Annual Quote

CareDx to Buy Transplant Dx Firm ImmuMetrix

NEW YORK (GenomeWeb) – CareDx, formerly called XDx, said late Wednesday that it has reached an agreement to acquire transplant diagnostic company ImmuMetrix for an undisclosed amount.

A development stage firm based in Palo Alto, Calif., ImmuMetrix was co-founded by Stephen Quake and Dan Seligson and has R&D programs and intellectual property in cell-free DNA, CareDx said. It added that ImmuMetrix has "pioneered contributions" in fields including single-cell gene expression, genome sequencing, non-invasive tests for heart transplant rejection, and approaches to sequencing and analyzing an individual's immune system.

According to ImmuMetrix's website, the company has an R&D program directed at cancer, transplantation, allergies, vaccine, autoimmunity, and asthma, and it has developed assays for immune repertoire profiling.

"We believe that this acquisition will further strengthen our position in organ transplant surveillance for both our current indication in heart with AlloMap and with other organs in our pipeline," CareDx President and CEO Peter Maag said in a statement.

AlloMap measures the expression levels of 20 genes from a blood sample and provides clinicians a tool for evaluating a patient's risk for a heart transplant rejection. The company launched the test in 2005, and the US Food and Drug Administration approved the test three years later.

"The combination of innovative cell-free DNA technology from ImmuMetrix, with the strong commercial channel provided by CareDx, will result in a new generation of diagnostic products to improve the care and treatment of transplant patients," Stephen Fodor, a board member of ImmuMetrix, said.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.